Clinical Trial Update: Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction chemotherapy with trifluridine/tipiracil and oxaliplatin for resectable esophageal or gastroesophageal junction adenocarcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Status: COMPLETED | Results posted: 2024-01-18